Not all sufferers with CLL demand therapy. Despite all modern advances, the iwCLL nonetheless recommends watchful observation for patients with asymptomatic disease.86 This recommendation is predicated on at the least two randomized trials evaluating observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FC